Inactive Instrument

Advaxis, Inc. Stock price Nasdaq

Equities

AYLA

US05465V1089

Sales 2023 * - Sales 2024 * - Capitalization 27.29M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 59 18-03-31
Director of Finance/CFO 50 23-10-18
Chief Tech/Sci/R&D Officer - 22-04-30
Members of the board TitleAgeSince
Chairman 64 17-10-31
Director/Board Member 57 04-10-31
Director/Board Member 79 17-11-30
More insiders
Ayala Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of Listeria monocytogenes (Lm)- technology antigen delivery products based on a platform technology that utilizes live attenuated Lm, bioengineered to secrete antigen/adjuvant fusion proteins. Its Listeria-based immunotherapies are designed for antigen delivery through a process of insertion of multiple copies of the tLLO-fusion protein into each extrachromosomal protein expression and secretion plasmid that makes and secretes the target protein right Inside the patient's antigen presenting cells to initiate and/or boost their immune response. It conducts clinical studies of Lm Technology immunotherapies in early prostate cancer. It identifies and works with collaborators and licensees for these programs and others for first-generation Lm immunotherapies, such as ADXS-HPV (AXAL) for HPV-associated cancer and ADXS-HER-2 for pediatric osteosarcoma.
Sector
-
More about the company